Get tested for
Parkinson’s disease with Duritect-PD™
If you suspect that you or someone you care for may have Parkinson's disease, a Duritect™ blood test could help you and your doctor arrive at a
diagnosis sooner.1
Why get tested
with Duritect-PD™?
Nearly 1 million people in the U.S. are affected by Parkinson’s disease (PD).2 One of the world’s fastest-growing neurological disorders, it affects people who live with it in many different ways.2,3
Duritect-PD™ is a simple blood test to quickly and reliably assess your risk of having Parkinson’s disease – helping you get on the path to a confirmed diagnosis earlier.1
Earlier diagnosis could lead to earlier intervention, which enables you to make changes that could improve your quality of life.4-6 It also gives you more time to make practical and legal preparations and ensure you get the support you need.7-8
Learn more on this page
- Features and benefits
- Step-by-step guide
- Start your journey to a diagnosis
About the test
Duritect-PD™ is a disease "risk assessment" test. It combines a simple blood test with machine learning analysis to assess your risk of having Parkinson’s disease.1,7
Your doctor can recommend Duritect-PD™ for you if appropriate. It is intended to be used as an aid in the diagnostic evaluation of adult patients aged 50+ who show signs or symptoms that could indicate Parkinson’s disease or other causes of cognitive decline.1
The test looks for the presence of specific autoantibodies in your blood as biomarkers of the disease.1
Features and benefits
Highly accurate
Convenient
Simple
Minimally invasive
Rapid
Affordable
Step-by-step guide
Here’s what to expect when you get tested with Duritect-PD™:
Here’s how to get tested with Duritect-PD™:
- Step 1: Make an appointment with your doctor.
- Step 2: Your doctor will assess your situation and determine whether Duritect-PD™ is appropriate for you.
- Step 3: Once the test is ordered, you can make the payment and provide a blood sample at your healthcare provider.
Your blood sample will be sent to Durin Life Sciences’ laboratory and analyzed using a combination of scientific approaches.
The test results are generally available 48–72 hours after the laboratory receives your blood sample.*
Your doctor will discuss the results with you to explain what they mean and recommend the best course of action.
Your results will show either an increased risk or a typical risk of Parkinson’s disease.3
- Increased risk: Your Parkinson's disease risk score indicates that you have a higher probability of having Parkinson's disease pathology.
- Typical risk: Your Parkinson's disease risk score indicates that you have a typical probability of having Parkinson's disease pathology.
Whether you have an increased risk or a typical risk, your doctor will help determine what your next steps should be.
You may be sent for a repeated test in some cases or more secondary tests to confirm the diagnosis and to rule out other causes of your symptoms.
Start your journey
to a diagnosis
If your doctor has recommended Duritect-PD™, taking the test is a proactive step toward understanding your health and receiving the right care.
Getting reliable information about the possibility of having Parkinson’s disease will empower you and your doctor to manage your health and make timely decisions.
All you have to do to move forward is pay for the test and have a blood sample taken. Act now to pursue a diagnosis as soon as possible.
CSO Durin Life Sciences
Abbreviations and references
*Delays in the delivery of samples to the laboratory may impact the turnaround time for results.
References
- [Duritect-AD™. Indications for use. Durin Life Sciences. 2024.]
- Yang W, Hamilton JL, Kopil C, et al. Current and projected future economic burden of Parkinson’s disease in the U.S. NPJ Parkinson’s Dis. 2020;6(15).
- Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson’s pandemic. J Parkinson’s Dis. 2018;8:S3-S8.
- Li G, Huang P, Cui S-S, et al. Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson’s disease patients. Translat Neurodegen. 2022;11(6).
- Arora S, Santiago JA, Bernstein M, Potashkin JA. Diet and lifestyle impact the development and progression of Alzheimer’s dementia. Front Nutr. 2023;10:1213223.
- Rees RN, Acharya P, Schrag A, Noyce AJ. An early diagnosis is not the same as a timely diagnosis of Parkinson’s disease. F1000 Res. 2018;7(F1000 Faculty Rev):1106.
- Gaster B, Pope TM. Guiding the future: rethinking the role of advance directives in the care of people with dementia. Hastings Cent Rep. 2024:54 (Suppl 1):S33–S39.
- Nasreddine Z, Garibotto V, Kyaga S, Padovani A. The early diagnosis of Alzheimer’s disease: a patient-centred conversation with the care team. Neurol Ther. 2023;12:11–23.
- Duritect™’s analytical and clinical validation data, company internal, 2025.